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Sporadic inclusion body myositis (sIBM) is considered the most common acquired myopathy aged over 50 years. The disease is
characterized by a particular process of muscle degeneration characterized by abnormal deposit of protein aggregates in association
with inflammation. The aim of this study was to present clinical and muscle histopathological findings, including immunostaining
for LC3B, p62, 𝛼-synuclein, and TDP-43, in 18 patients with sIBM. The disease predominated in males (61%) and European
descendants, with onset of clinical manifestations around 59 years old. The most common symptoms were muscle weakness,
falls, dysphagia, and weight loss. Hypertension was the main comorbidity. Most of the cases presented with paresis predominantly
proximal in lower limbs and distal in upper limbs. Immunosuppressive treatment showed to be not effective. Muscle histological
findings included dystrophic changes, endomysial inflammation, increased lysosomal activity, and presence of rimmed vacuoles
and of beta-amyloid accumulation, in addition to high frequency of mitochondrial changes. There was increased expression of
LC3B, p62, 𝛼-synuclein, and TDP-43 in muscle biopsies. The sIBM has characteristic clinical and histological findings, and the use
of degeneration and autophagic markers can be useful for the diagnosis.
1. Introduction
Sporadic inclusion body myositis (sIBM) is a late-onset
form of myopathy classified in the group of inflammatory
myopathies. It is considered the most common form of
myopathy in patients over 50 years of age, with a prevalence
of 3,5 in 100,000 individuals and a male/female ratio of 3 : 1
[1, 2]. Whereas 18–20% of patients develop symptoms before
60 years of age, it is important to consider the diagnosis of
sIBM in all patients with consistent symptoms after 30 years
old [3, 4]. Clinically, the disease affects predominantly the
quadriceps and the gastrocnemiusmuscles in the lower limbs
and the finger flexors in the upper limbs [5–8]. The skeletal
muscle abnormalities include an endomysial inflammatory
reaction in association with degenerative changes character-
ized by the presence of rimmed vacuoles, intracytoplasmic
inclusions formed by the accumulation of abnormal proteins,
𝛽-amyloid deposits, andmitochondrial changes [5, 9, 10].The
presence of such degenerative alterations suggests that the
disease might be actually a form of muscular degeneration
with an associated inflammatory reaction.Thiswould explain
the absence of a response to immunosuppressive therapy [11,
12]. However, the precise relationship between degenerative
and inflammatory mechanisms is still not clear, and several
lines of researches have shown that the inflammatory process
could induce or even worsen the degeneration [13].
Some of the degenerative abnormalities include abnor-
mal deposition of protein aggregates formed from amyloid
precursor protein (APP), 𝛽-amyloid 42, phosphorylated tau
(tau-p), 𝛼-synuclein, 𝛼-B-crystallin, clusterin, presenilin 1,
gelsolin, apolipoprotein E (APOE), 𝛾-tubulin, and numerous
proteins related to oxidative stress, among them the heat
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shock proteins [10–15]. Interestingly, there are many simi-
larities between the degenerative changes observed in sIBM
and in Alzheimer’s and Parkinson’s diseases.These anomalies
include abnormal accumulation of congophilic inclusions
and many proteins with similar posttranslational modifica-
tions (i.e.,𝛼-synuclein, p62, TDP-43, LC3B, and ubiquitin), in
associationwith inhibition of 26S proteasome and autophagic
systems (defective lysosomal degradation) [11–15]. The inhi-
bition of these two degradative systems contributes to the
formation of the protein aggregates (nondegraded), amyloid
accumulation, and cytoplasmic vacuolization [11, 12].
Due to its slow progression and unspecific results in
blood tests, diagnosis of sIBM is frequently delayed, and in
many cases the main initial diagnoses include polymyositis
or neurogenic disorders. The most commonly used specific
diagnostic criteria for sIBM were published by Griggs et al.
in 1995 [16]. However, in several patients with typical clinical
sIBM the muscle biopsies do not have the histopathologic
findings. In an attempt to increase the sensitivity of diagnosis,
several new criteria were proposed: (1) diagnostic criteria of
the European Neuromuscular Center (ENMC) to sIBM in
1997 [17]; (2) diagnostic criteria of Neuromuscular Disease
Center at theMedical Research Council (MRC) in 2008/2009
to sIBM [18, 19]; and more recently (3) diagnostic criteria
of ENMC to sIBM-2011 [20]. In a recent study, Brady et al.
[21] found that the criteria proposed by ENMC-2011 were the
most sensitive to sIBM, diagnosing 88% of cases, compared
with 76% of Griggs criteria and 27% of ENMC-1997 criteria
[21]. This same group of researchers suggested a flowchart
diagnosis for sIBM based on pathologic findings [22]. From
24 diagnostic categories for sIBM proposed since 1987, Lloyd
et al. [23] identified 12 categories with very high specificity
of 97% or more, but some had precarious sensitivity as
low as 11%. The best performing category was ENMC-2011
(probable) with a sensitivity of 84% [23].
This study aims to present clinical and skeletal muscle
histological findings in 18 patients with sIBM. Additionally,
autophagy and neurodegeneration markers were applied in
the muscle biopsies to detect immunohistochemical abnor-
malities that could be potentially useful in differentiating
sIBM from other forms of inflammatory myopathies.
2. Patients and Methods
2.1. Patients andClinical Evaluation. Weevaluated 18 patients
with clinical and histological diagnosis of sIBM from two
of the largest neuromuscular centers in the city of Sa˜o
Paulo, Brazil, during the period of 2013 to 2016. Diagnostic
criteria proposed by Griggs et al. [16] were used for the
inclusion of patients in the study. Patients with a family
history of hereditary IBM and with any other neuromuscular
disease were excluded.This study was approved by the Ethics
Committee for Research Project of our institution.
Patients were evaluated according to general clinical
history, age of onset of symptoms, initial symptoms, evo-
lution of the symptoms, and the presence of depressive
symptoms, disturbance of equilibrium, dysphagia, dyspnea,
and weight loss. Patients were asked about family history
and previous use of medications. The presence of weakness
was assessed through neurological examination, including
assessment using the Medical Research Council (MRC) scale
of muscle strength and motor functional condition using
the modified Rankin scale [24]. The effects of functional
motor deficits under activities of daily living (ADL) were
assessed by the simplified Barthel index [25]. Most patients
were evaluated on more than one occasion with an interval
of at least 6 months.
Ancillary examinations done in different laboratories or
services were recorded, including serum creatine phosphok-
inase (CK) measurement, rheumatologic tests, tumor mark-
ers, virus serology, and electromyography/nerve conduction
study (EMG/NCS).
2.2. Muscle Biopsy and Staining Reactions. All patients had
muscle biopsy examination performed between 2004 and
2016 (Table 4). Biopsies 1a, 4a, 5a, 16, 17, and 18 were
performed at the deltoid muscle; 1b, 2, 7b, 8, 9, 11b, and
15 were performed at biceps brachii muscle, and the others
were performed at vastus lateralis. The methodology used
for processing the biopsies followed standard procedures:
after they are removed, muscle fragments are snap frozen in
isopentane frozen in liquid nitrogen and stored in a freezer
at −80∘C before processing. The fragments are sequentially
sectioned in coronal position in cryostat at a temperature
of −25∘C, with a thickness from 6 to 8 microns. The frozen
sections were stained with hematoxylin and eosin (HE),
modified Gomori trichrome, periodic acid-Schiff (PAS), and
“oil red” O (ORO). In addition, the histochemical reactions,
NADH-tetrazolium reductase (NADH-TR), succinate dehy-
drogenase (SDH), cytochrome c oxidase (COX), adenosine
triphosphatase (ATPase) in pH acid (4.3 and 4.6) and alkaline
(9.3), and acid phosphatase, were done. The reactions were
performed according to techniques well established in the
literature [26].
The slides were analyzed qualitatively by lightmicroscopy
according to the variability in fiber size, increase in
endomysial/perimysial connective tissue, proportion of fibers
with nuclear centralization, and the presence of fibers with
necrosis and/or macrophagy, regenerating fibers, inflamma-
tion (endomysial, perimysial, and perivascular), vacuolar
formation, rimmed vacuoles, and mitochondrial alterations
(RRF: ragged red fibers, SDH-positive fibers, and COX-
negative fibers). In addition, the presence of neurogenic
alterations (angulated fibers, fiber type grouping), internal
cytoarchitecture changes (oxidative defects, minicores, and
moth-eaten and lobulated fibers), and lipids and glycogen
accumulation were assessed. These aspects were evaluated
qualitatively as present (P) or absent (A), as well as quan-
titatively, according to mild (+), moderate (++), and severe
(+++) degrees. Congo-red reaction was also carried out
in alkaline pH, useful in identifying amyloid deposits, via
immunofluorescence microscopy with a Texas red filter [27].
2.3. Immunohistochemical Reactions. The frozen sections
were subjected to immunohistochemistry using polymer
amplification system Novolink (Novolink kit max polymer
detection system, Novocastra, RE7140 RE7150-K or K-
code, Newcastle upon Tyne, UK) followed by staining with
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DAB (diaminobenzidine). The slides with muscle samples
remained for 10 minutes at room temperature to dry, and
sections were incubated in a blocking solution at room
temperature (Peroxidase Block Novocastra, RE7101 code,
Newcastle upon Tyne, UK) for 5 minutes. After washing in
TBS three times for 5 minutes, the slides were incubated
with the primary antibodies diluted in the second blocking
buffer (Protein Block) for 1 hour at room temperature.
The slides were washed two times in TBS of 5 minutes
and incubated with primary antibody blocking solution
(Post Primary, Novocastra, RE7111 code, Newcastle upon
Tyne, UK) for 20 minutes, followed by washing in TBS
two times for 5 minutes and incubation with polymer
(polymer Novolink, Novocastra, RE7112 code, Newcastle
upon Tyne, UK) for 20 minutes. After washing in TBS two
times for 5 minutes, the reactions were revealed using DAB
(diaminobenzidine) [50 uLDABChromogen-dilutedRE7105
code 1mLNovolinkDABSubstrate Buffer-Polymer-RE7143
code Novocastra, Newcastle upon Tyne, UK] for about 2
to 5 minutes and subsequently rinsed in running water two
times for 2 minutes to block DAB, followed by dripping
with Harris hematoxylin for counter-staining and finally
dehydration and mount sections. The primary antibodies
used were anti-CD68 (Mouse/EBM11, DAKO/M0718, 1 : 100),
anti-CD4 (Mouse/4B12, DAKO/M7310, 1 : 100), anti-CD8
(Mouse/C8/144B,DAKO/IS623, 1 : 100), anti-MHC-I (Mouse/
W6/32, DAKO/M0736, 1 : 100), anti-LC3B (Rabbit, Sigma/
L7543, 1 : 100), anti-𝛼-synuclein (Rabbit, Sigma/S3062,
1 : 100), anti-p62/SQSTM1 (Rabbit, Sigma/P0068, 1 : 100),
anti-phospho TDP-43 (Mouse/11-9, Cosmo Bio/pS409/410,
1 : 5000), anti-𝛾 Sarcoglycan (Mouse/35DAG/21B5, Novocas-
tra/ab49811, 1 : 100), anti-𝛼 Sarcoglycan (Mouse/Ad1/20A6,
Novocastra/NCL-L-a-SARC, 1 : 100), anti-dystrophin 1 (rod
domain) (Mouse/Dy4/6D3, Novocastra/NCL-DYS1, 1 : 100),
anti-dysferlin (Mouse/Ham3/17B2, Novocastra/NCL-Ham-
let-2, 1 : 100), and anti-caveolin-3 (Rabbit, Abcam/ab2912,
1 : 100). To standardize the immunohistochemical reactions,
muscle biopsy from a patient with normal histological
diagnosis (case 19), two patients with histological diagnosis
of dermatomyositis (cases 20 and 21), and two with
histological diagnosis of polymyositis (cases 22 and 23) were
used. The individual with normal histological diagnosis was
submitted to muscle biopsy due to clinical complaint of
fatigue.
2.4. Statistical Analysis. For the statistical calculation, we
used the Pearson and Spearman coefficients, considering a
relationship to be statistically significant when 𝑝 < 0.05.
3. Results
3.1. Clinical Findings. It was observed that sIBMwas predom-
inant in males (61% of cases). Approximately 83% (𝑛 = 15)
of patients were European descendants. The average age of
onset of symptoms was 58.8 ± 10.9 years old (ranging from
38 to 75 years old). In 17% of patients (𝑛 = 3), the symptoms
began before the age of 45, in two men (40 and 42 years old)
and one female (38 years old). In 56% of cases, the symptoms
appeared after 60 years of age (Table 1).
The average time between the onset of symptoms and the
sIBM diagnosis was 7.4 ± 7.1 years (ranging from 11 months to
31 years). One patient (case 16), after a period of treatment for
inflammatory myopathy, was diagnosed with motor neuron
disease (MND) and later with diagnosis of sIBM after muscle
biopsy.
The most common symptoms were muscle weakness,
postural instability with falls, dysphagia, and weight loss.
Dysphagia was a common symptom found in 67% of patients
(𝑛 = 12) (Table 1). Weight loss was observed in nine patients
(50%). Thirteen patients (72%) had complained of frequent
falls, often interpreted by patients as disturbance of equilib-
rium, and in six of them this complaint was present in the first
year of the manifestations (Table 1). Dyspnea was reported
by 28% (𝑛 = 5) of patients (Table 1). One of the patients had
obstructive sleep apnea and chronic obstructive pulmonary
disease (COPD) secondary to smoking, and he was using
home oxygen therapy. Two other patients also had COPD,
but with spirometry demonstrating restrictive disorder. Case
4 had resting dyspnea complaints, but normal spirometry,
while Case 5 had asthma. The presence of dyspnea had a
moderate correlation with worse motor function (𝑝 < 0.04),
greater ADL limitations (𝑝 < 0.02), and no apparent relation
to the time of disease evolution.
The main comorbidities observed in this study were
hypertension (𝑛 = 13/72%), diabetes mellitus type 2 (𝑛 =
4/22%), osteopenia/osteoporosis (𝑛 = 4/22%), dyslipidemia
(𝑛 = 4/22%), hyperuricemia/gout (𝑛 = 4/22%), COPD
(𝑛 = 3/17%), benign prostatic hyperplasia (𝑛 = 3/17%), and
glaucoma without family history (𝑛 = 3/17%). Other con-
ditions observed in our patients were hypertriglyceridemia,
colonic diverticulosis, cataract, acute myocardial infarction,
obstructive sleep apnea syndrome, hypothyroidism, ery-
thematosus tumidus (lymphocytic infiltration of Jessner),
herpes zoster, radical prostatectomy, Wolf-Parkinson-White,
restless legs syndrome, conservative treatment for herniated
lumbar disc, surgical treatment for lumbar disc herniation,
ocular toxoplasmosis, ischemic stroke, prior HTLV-I infec-
tion, squamous cell carcinoma (face), sarcoidosis, migraine
with aura, coronary insufficiency, asthma, total hysterec-
tomy (myoma), peripheral neuropathy (diabetic), pulmonary
hypertension, idiopathic cirrhosis, interstitial pneumopathy,
pulmonary thromboembolism, central retinal vein thrombo-
sis, and nephrolithiasis.
The muscular involvement pattern was characterized by
paresis predominantly proximal in lower limbs and distal in
upper limbs (Figure 1). The measurement of muscle strength
of patients according to the MRC scale is shown in Table 2.
All sIBM patients had involvement of the wrists flexors
(except case 13), hand fingers flexors, and leg extensors
muscles. Other muscle groups involved in most cases were
the biceps brachii, triceps brachii, thigh flexors (particularly
the iliopsoas muscle), thigh extensors, and leg flexor muscles.
The flexors of the feet were affected in 56% of cases. One
interesting finding observed in the case 2 was the weakness
of the lower abdominal muscles, accompanied by Beevor’s
sign described as upper deviation of the umbilicus in the
evaluation of abdominal skin reflex (Figure 1(d)).
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Figure 1: Clinical findings of patients with sIBM. Intense atrophy of quadriceps femoris muscle in case 4 (a) and case 1 (b), global atrophy of
lower limbs in case 16 (c), Beevor’s signal in case 2 (d), atrophy of upper limbs in case 2 (e), atrophy of finger flexors in cases 16 (f) and case 7
(g), and bilateral atrophy of quadriceps femoris in case 7 (h).
The functional status of patients is displayed in Table 1, in
which the results of two assessments with an interval of 12 to
18months are presented.We only found statistical correlation
between the time of disease progression and theBarthel Index
(𝑝 = 0.033), demonstrating the highest degree of dependence
in ADL with the evolution of sIBM. All other relationships
were not statistically significant. Some cases were evaluated
only one time (cases 4, 13, 15, 16, 17, and 18). In all other cases,
worsening of disability and increase of limitations of ADL
were observed after 12 to 18 months of the first evaluation.
Immunosuppression was not effective over the long term in
most of the patients with sIBM. Fifteen patients (83%) had
the initial diagnosis of inflammatory myopathy, undergoing
several medical treatments described in Table 3.
3.2. Ancillary Exams. Theabsolute values of the highest levels
of CK were among 214U/L and 2,656U/L, and the relative
values for the upper limit of normality (ULN) ranged from
1,11 to 9,48 × ULN.
EMG/NCSwas performed in all cases.The patterns found
in 12 patients (67%) were polyphasic potentials to slight
contraction, paradoxical interference potential to maximal
contraction, rest-intense activity characterized by fibrillation,
and the presence of motor unit potential with increased
amplitude and long duration. Reduction in sensory and/or
motor nerve conduction velocities, excluding the compres-
sive mononeuropathies (e.g., carpal tunnel syndrome, ulnar
nerve at the elbow, and the common peroneal nerve at the
fibular head) were found in 33% of cases. Case 16 held two
EMG/NCS, and the first was interpreted as motor neuron
disease. Surface electromyography was performed in two
patients with dysphagia, one had normal findings (case 5)
and the other (case 4) had normal findings at rest, but with
increased muscle contraction in laryngeal extrinsic muscles
of swallowing saliva. This finding is related to the transition
of the pharyngeal phase to the esophageal phase, showing a
mild to moderate oropharyngeal dysphagia. Another patient,
who also had dysphagia, underwent nasolaryngofibroscopy
that showed esophageal-laryngeal reflux (case 2).
3.3. Histological and Histochemical Analysis. Of the 18 cases,
seven were submitted to two procedures (1a, 1b, 4a, 4b, 5a,
5b, 7a, 7b, 10a, 10b, 11a, 11b, 12a, and 12b), with a total of
25 examined biopsies. The information about the biopsied
muscle, biopsy date, and the initial histological diagnosis is
presented in Table 4.
Representative images of histological and immunohisto-
chemical findings of the sIBM cases are shown in Figures 2
and 3. All sIBM biopsies showed preservation of the fiber-
typing distribution pattern, variation in size of the fibers,
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Table 3: Drugs used by patients with sIBM, duration of treatment, side effects, and clinical and laboratory changes related to the treatment.
Case Drug Duration Side effects Clinical and laboratorychanges
1
AZAT 150mg/day 6 months Chills + prostration No
PRED 60mg/day 8 years No No
PRED 60mg 8/8
hours 90 days Anasarca No
Mofetil 3 months
Diarrhea +
consumptive
syndrome
No
MTX 20mg/week 3 years No No
2 PRED 60mg/day 9 days Anasarca No
3
IVIG 400mg/kg PT 2 days (for 2x) No No
Abatacept 10 doses No Light motorimprovement NS
Leflunomide
20mg/day 3 years No No
PRED 30mg/day 6 years No No
Cyclophosphamide 1 year No No
AZAT until
250mg/day 1 year Leukopenia No
Cyclosporine 2x pulse therapy No No
4
Deflazacort
45mg/day 1 month Weakness worsens No
Deflazacort
30mg/day 4 months No No
5 MTX 7,5mg/week 4 years No No
6
PRED 60mg/day 1 year No No
AZAT 250mg/day +
PRED 20mg/day 2 months No No
MP 1 gram PT for 2 days No Light motorimprovement NS
8
AZAT Pancytopenia No
Cyclosporine Incoercible vomit No
PRED 40mg/day 3 years Drug Cushing’ssyndrome No
MP 1 grama PT for 2 days No Partial improvement ofdysphagia
MTX 1 year Gastric intolerance No
10
AZAT 150mg/day 1.5 years No No
MTX 20mg/week +
PRED 60mg/day 2 years No No
Rituximab 1 cycle No No
11
MP 1 gram PT 5 days No No
PRED 40mg/day 6 months No Reduction CK/noimprovement
MTX + AZAT 4 years No Reduction CK/noimprovement
12 IVIG 400mg/kg 2 years No No
13
PRED (maximum
dose 80mg/day) 8 years Edema + weight gain No
MP 1 grama + IVIG
400mg/kg PT for 2 days/each No
Light motor
improvement NS
AZAT 1.5 years No No
8 BioMed Research International
Table 3: Continued.
Case Drug Duration Side effects Clinical and laboratorychanges
14 MTX 1 month Gastric intolerance No
16
MTX 1 year No No
Coenzyme-Q10 15 months No No
Riluzole 15 months No No
17 PRED 20mg/day 6 months No No
18 PRED 60mg/day +folic acid 5mg/day 9 months Edema + weight gain
Light motor
improvement NS
AZAT = azathioprine. PRED = prednisone. MTX = methotrexate. IVIG = intravenous human immunoglobulin. MP = methylprednisolone. CK = creatine
phosphokinase. NS = nonsustained. PT = pulse therapy.
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Figure 2: Histological findings inmuscle biopsy of patients with sIBM. (a) Endomysial inflammatory reaction (arrows) and global dystrophic
pattern (case 4(b)) (H&E). (b) Endomysial inflammatory reaction (white arrow) and rimmed vacuoles (black arrow) (case 4(b)) (Gomori’s
trichrome). (c) Oxidative defects (case 7(b)) (NADH). (d) CytochromeC oxidase deficiency (arrows) (case 7(b)). (e) Intense acid phosphatase
reaction (case 6). (f) Positive Congo-red staining (arrows) (case 6).
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Figure 3: Immunohistochemical findings in muscle biopsy of patients with sIBM. (a) Presence of areas of positive staining for CD8-
lymphocytes (case 2). (b) Diffuse increase of histocompatibility antigen type I expression (case 2). (c) Increased LC3 expression in the vacuole
(arrow) (case 5(b)). (d) Increased alpha-synuclein expression in the vacuoles (arrows) (case 5(b)). (e) Increased TDP-43 expression in the
vacuoles (arrows) (case 5(b)). (f) Increased p62 expression in the vacuoles (arrows) (case 5(b)).
presence of rimmed vacuoles (except biopsies 1a, 4a, 7a, and
12a), increased nuclear internalization, endomysial inflam-
matory infiltration, increased reaction to acid phosphatase,
and unspecific changes at oxidative stains. Just over half
of the biopsies showed reduced labeling for COX or COX-
negative fibers. Four biopsies had RRF, and ten showed SDH-
positive fibers. Most of biopsies showed signs of necrosis
with increased macrophagy and increased endomysial and
perimysial connective tissue (Table 4). All cases had no signs
of lipid or glycogen accumulation. All cases of sIBM showed
signs of beta-amyloid accumulation with positive Congo-red
reaction (Figure 2(f)/Table 4). Congo-red reaction was not
performed in four biopsies (7a, 10a, 11a, and 12a) due to lack
of stored material.
3.4. Immunohistochemical Analysis. All sIBM and inflamma-
tory myopathy control cases showed increased labeling for
inflammatory markers (CD4, CD8, CD68, andMHC-I) (Fig-
ures 3(a) and 3(b)/Table 5). There was increased expression
of LC3B (autophagic marker), especially in the vacuoles, in
67% of sIBM cases (𝑛 = 12) (Figure 3(c)). The expression
was not increased in cases 6, 9, 12, 14, 17, and 18, as well as
in the controls (cases 19, 20, 21, 22, and 23). The expression
of p62/SQSTM1 (anti-p62) was positive in all cases of sIBM
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Table 5: Immunohistochemical findings of muscle biopsies in 18 cases with sIBM and controls.
Case CD68 CD4 CD8 MHC-I LC3B syn TDP-43 p62
1
a ++ + + +++ P P P P
b ++ + + + A P P P
2 +++ + ++ +++ P P P P
3 +++ + + ++ P P P P
4
a ++ + + +++ P P P P
b +++ + ++ +++ P P P P
5
a ++ + + ++ A P P P
b ++ ++ ++ ++ P P P P
6 +++ ++ + ++ A P P P
7
a + + + ++ U U U U
b ++ + ++ ++ P P P P
8 +++ + + +++ P P P P
9 ++ + + ++ A P P P
10
a U U U U U P U P
b ++ + ++ ++ P P P P
11
a U U U U U U U U
b + + + ++ P P P P
12
a U U U U U U U U
b ++ + + +++ A P P P
13 ++ + + ++ P A P P
14 ++ + + ++ A P P P
15 ++ + +++ +++ P P P P
16 ++ + + +++ P P P P
17 ++ + + +++ A A P P
18 ++ ++ ++ +++ A P P P
Controls
19 ++ A A A A A A A
20 A + + ++ A A A A
21 ++ + + + A A A A
22 + + + +++ A A A A
23 ++ + ++ +++ A A A A
A= absent. P = present. U = undone. LC3B =microtubule-associated protein light chain 3. Syn = alpha-synuclein. TDP-43 = transactive response DNA binding
protein 43 kDa. P62/SQSTM1 protein = p62/sequestosome 1. MHC-I = main complex histocompatibility type 1. CD4 and CD8 = lymphocytes markers. CD68
= macrophage marker. +: mild. ++: moderate. +++: severe.
(Figure 3(f)). Expression of 𝛼-synuclein staining was positive
in about 89% of sIBM cases (Figure 3(d)). The expression
of anti-phospho TDP-43 (anti-TDP-43) was positive in all
cases with sIBM (Figure 3(e)), with no reaction in the
controls. The positivity for anti-TDP-43 was predominantly
in vacuoles, while positivity for anti-𝛼-synuclein occurred
both in the vacuoles and in the nucleus of some muscle
fibers. Immunohistochemical reaction tomembrane proteins
(dystrophin and sarcoglycans), dysferlin, and caveolin-3 was
normal in all tested cases. Immunohistochemical reactions
for LC3B, TDP-43, p62, and 𝛼-synuclein were not performed
in four biopsies (7a, 10a, 11a, and 12a), as well as inflammatory
markers in three biopsies (10a, 11a, and 12a) due to lack of
stored material.
3.5. Comparison between the Main sIBM Diagnostic Criteria.
All sIBM cases included in this study met the criteria
proposed by Griggs et al. [16], as well as the diagnostic
criteria of the ENMC-1997 for sIBM [17] and Neuromuscular
Diseases Center of the Medical Research Council (MRC)
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2008/2009 [19]. But when the diagnostic criteria proposed
by the ENMC in 2011 [20] were used, three cases (cases 1, 9,
and 10) could not be included because the patients started the
symptoms before they were 45 years old.
4. Discussion
We present here clinical and skeletal muscle pathological
findings of patients with sIBMwhomet the classic diagnostic
criteria proposed by Griggs et al. [16]. In this study, sIBM
predominated in males (61% of cases), similar to the other
studies in the literature [1, 2, 28], with onset of clinical
manifestations at 58.8 years of age (±10.9). Forty-four percent
of patients had symptoms before the sixth decade of life; other
studies have indicated that about 18–20% of patients with
sIBM develop symptoms before that age [29]. Furthermore,
three patients (17%) had symptoms before 45 years, which
excludes these patients from the inclusion criteria of the
ENMC-2011 for sIBM, even considering that these patients
have presented all clinical and histological findings from
the other criteria frequently used by others (Griggs-1995,
ENMC-1997, and MRC-2008/2009). Recently described as
the diagnostic criteria with higher sensitivity and specificity
[21, 23], the ENMC-2011 excludes patients with early age of
45 years even with clinical and pathological confirmation.
Thus, a change in ENMC-2011 criteria—that is, considering
age > 35 years old and not >45 years old as in the original
publication—would increase the diagnostic sensitivity for
sIBM in our study from 83% to 100%.These facts would occur
in several other series, including a recent Chinese report that
included a patient with an onset of symptoms at 38 years old
and in which 11% of patients were between 40 and 49 years
old [28]. However, it should be considered that an early onset
of the manifestations implies a more detailed investigation
into other conditions that may mimic sIBM, such as muscu-
lar dystrophies, myofibrillar myopathies, and inflammatory
myopathies of other etiologies. A critical analysis of the sIBM
criteria was recently published and the authors stated that any
currently accepted diagnostic criteria will be shown to have
“missed” patients with atypical features [30].
The identification of cN1A antibodies in sIBM might be
useful to increase the diagnosis specificity [31–33]. Despite
some studies have indicated that moderate reactivity was
70% sensitive and 92% specific and high reactivity was 34%
sensitive and 98% specific for the diagnosis of sIBM [31–33],
such autoantibodies are also found in autoimmune rheumatic
diseases (dermatomyositis, systemic lupus erythematosus,
systemic sclerosis, Sjo¨gren’s syndrome, and polymyositis)
[34]. Unfortunately, in our country, this antibody is not yet
widely available, so it was not possible to include this data in
this study. Certainly, future sIBM criteria would consider the
inclusion of more specific newly recognized autoantibodies
to increase the specificity of the diagnosis.
In our study, the average time between the onset of
symptoms and the sIBM diagnosis was 7.4 ± 7.1 years. These
findings point out that in our country, as noted in many
other series, sIBM was underdiagnosed. In addition, 83%
of our patients had the initial diagnosis of polymyositis.
These cases were submitted to severe drug treatments already
demonstrated to be ineffective for sIBM, often causing con-
siderable side effects. One of the factors that most confuses
the diagnosis is the EMG/NCS interpretation. Some sIBM
cases presented EMG/NCS reports suggesting polymyositis.
One of our caseswas diagnosed byEMG/NCS as polymyositis
and was treated with immunosuppression. In this patient,
the EMG/NCS was repeated and the diagnosis was changed
to motor neuron disease. Many patients get the diagnosis of
motor neuron diseases because they present, together with
the electrophysiological misinterpretation, asymmetric distal
motor predominance in the upper limbs, dysphagia, dyspnea,
weight loss, and dysphonia in some cases [35]. EMG/NCS
is an examiner-dependent method and can often hinder the
diagnosis and generate unnecessary treatments. Eventually,
studies with quantitative EMG/NCS could improve the sen-
sitivity of electrophysiological diagnostic of sIBM.
In our study, the most frequent complaints of the patients
regarding early symptoms were weakness of one or more
extremities, presented in 94% of our cases. Most commonly,
patients reported bilateral involvement of the lower limbs
(39%), followed by noncharacterized weakness in the four
limbs (28%) and initial weakness in one of the lower limbs
(17%).One patient presented onset of symptomswith dyspha-
gia, another with simultaneous weakness in the upper limbs,
and another with initial weakness in one of the upper limbs.
This predominance for weakness in the proximal muscles of
the lower limbs is well demonstrated in the literature [4, 23].
Another frequent complaint of patients (72%) in our
study was related to postural instability during gait and falls
from height, which was often interpreted as disturbance of
equilibrium; just under half of the patients cited this as an
early symptom, although it has not been described in the
literature. Other relevant symptoms were dysphagia (67%),
weight loss (50%), and depressive symptoms (33%), the latter
preceding or following the onset of the classical symptoms
of sIBM, a fact that points to another similarity with neu-
rodegenerative diseases such as Alzheimer and Parkinson
diseases and may even arise before other complaints. When
the relationship between the Barthel Index and the sIBM
development time was analyzed, it was noted that the time
to disease progression was inversely proportional to the
Barthel index (𝑝 = 0.033). All other correlations showed
no statistically significant relationship, most probably due
to the small number of patients. The presence of depressive
symptoms andweight loss predominated in the first year after
the onset of symptoms.
Themajor comorbidity associated with sIBMwas arterial
hypertension (72%), possibly being aggravated in some cases
by the side effects of previously prescription drugs, mainly
oral corticosteroids. Approximately 22% of patients had
diabetes mellitus type 2, osteopenia/osteoporosis, hyperlipi-
demia, and hyperuricemia/gout, and some of these also
were exacerbated by drug therapy. The presence of a large
number of comorbidities in these cases indicates the need
for extra care when prescribing immunosuppressive drugs.
In addition, physicians should reassess the maintenance
of immunosuppression when no therapeutic response is
noticed.
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Interestingly, despite the relationship described between
sIBM and serum positivity for antibodies to hepatitis C virus
[36–38], none of the patients in this series had positive
serology for hepatitis C. In another Brazilian study with 30
patients with sIBM, one patient had positive serology for
hepatitis C and two for HIV [29]. Freitas et al. [39] reported
a coexistence of sIBM with HIV infection, and Cupler et al.
[40] reported two cases with this association. In our study,
only one patient had viral seropositive forHTLV-I, whichwas
also reported in an American patient [40]. Another patient
developed shingles during the course of the disease and the
immunosuppressive treatment.
Although sIBM may present as a paraneoplastic condi-
tion, or as coexisting with it, only one patient in our study
had prior squamous cell carcinoma in the face. In another
Brazilian study with 30 patients with sIBM, four patients had
concurrent cancer; two with prostate carcinoma, one with
follicular adenocarcinoma ovarian, and the other with breast
adenocarcinoma [29].
One case in our study had an interesting history of
pulmonary sarcoidosis in 1979, which was treated at the
time and remained asymptomatic until then. This patient
developed early symptoms of sIBM after about 30 years of
the pulmonary event, but with no granulomatous findings
on muscle biopsy. Similar cases have been rarely described in
the literature [41–45]. Another patient of our series presented
histopathologic diagnosis of lupus erythematosus tumidus,
lymphocytic infiltration of Jessner in skin biopsy, and no
evidence of systemic lupus erythematosus, a situation not
described in the literature until now.
We characterized the pattern of muscle impairment in
patients with sIBM as paresis with proximal predominance
of lower limb (quadriceps femoris and flexor muscles of
the thigh) and distal upper limb (flexors of the wrists and
hand fingers), a fact well characterized in the literature [4–6].
There was also a significant impairment of the biceps brachii,
triceps, iliopsoas, thigh extensors, and leg flexor muscles.
Just over half of the patients had involvement of the foot
flexor muscles, most commonly seen in the later stages of
the disease, while 17% of patients had weakness in one of the
lower limbs as the initial symptom. Such muscle impairment
corresponds to the typical pattern described in sIBM [4–6]
and is included in the clinical diagnostic criteria.
Only one patient hadweakness of the abdominalmuscles,
predominantly in the bilateral lower level, with the presence
of upward deviation of the umbilicus in the evaluation of
skin-abdominal reflex bilaterally, also called Beevor’s sign.
This sign was recently described in sIBM [46].
Our study showed that 67% of patients had dysphagia. A
study of Li et al. [28] including 28 patients with sIBM found
dysphagia in only 7% of patients. This complaint should be
actively questioned by the patient because most of them do
not notice the difficulty in swallowing, whichmay explain the
low incidence in other series. In the study of Alverne et al.
[29], only 13% of patients had weight loss without apparent
cause, while about 40% of cases in our study progressed with
weight loss.
A retrospective analysis of immunosuppressive therapies
used in some of our cases did not appear to significantly
influence motor decline or worsen general symptoms, while
four patients with sIBM in this series showed mild, but
not sustained improvement. One patient had mild motor
improvement, but for less than six months after ten doses
of abatacept. Two patients had symptomatic improvement
after intravenous methylprednisolone; one with no sustained
motor improvement of less than 6 months and the other with
partial improvement of dysphagia lasting less than 12months.
Another patient received intravenousmethylprednisolone for
two days, followed by intravenous immunoglobulin (IVIG)
for two days and also showed a slight improvement with
motor function worsening after six months. Another patient
showed a large drop in CK serum levels during use of
prednisone and later with the combination of methotrexate
and azathioprine, but without any clinical improvement. In
addition to the case described with partial and not sustained
motor improvement, two patients received IVIG without
any clinically change. A recent publication evaluated six
patients undergoing treatment with subcutaneous human
immunoglobulin, and all showed improvement in muscle
strength and resolution of dysphagia. Four patients got worse
before 12months, and the other two got worse after 12months
[47].
All patients with sIBM showed increased CK serum levels
that were 10 times lower than ULN levels (below the limits
proposed in the diagnostic criteria) [16, 20, 21].
In our series, seven cases were submitted to repeated
muscle biopsy procedures, three of which were done in our
service (cases 7, 10, and 12), including cases 7 and 12 for
lack of diagnosis and case 10 for an unknown reason (as the
patient already had sIBM diagnostic in the first biopsy). One
case was assessed with external neurologist and underwent
a new procedure for an unknown reason (case 11). In three
other patients (cases 1, 4 and 5), two underwent a newmuscle
biopsy due to a lack of histological diagnosis and one did
so for an unknown reason. The interval between biopsies
from the same patient ranged from 2 months to 12 years.
Three cases were subjected to biopsy in the deltoid muscle,
two of which had no strength deficits in this muscle. The
best place for a muscle biopsy, if not guided by imaging, is
the muscle with impairment of strength combined with no
marked atrophy.
All muscle biopsies of the patients presented with nor-
mal distribution of fiber types, variable dystrophic changes,
endomysial and perimysial inflammatory reaction, rimmed
vacuoles, and increased staining for acid phosphatase. Other
relevant histological findings were the presence of mito-
chondrial changes (83%) including the presence of reduced
staining for COX, SDH-positive fibers, and RRF. In addition,
all biopsies had Congo-red positive staining indicating beta-
amyloid accumulation. All the above histological findings
are characteristic of sIBM and are indicated at the inclusion
criteria.
All cases with sIBM and inflammatory controls were
positive for inflammatory markers, which does not help
to differentiate between them. In particular, MHC-I and
MHC-II are useful markers to characterize inflammatory
myopathies in general. In this study we used only MHC-
I, but not MHC-II, and an overall increase in the staining
14 BioMed Research International
was detected in all cases, including in the controls with other
forms of inflammatorymyopathy. But when the degeneration
and autophagy activation markers were used, they were
positive in all cases with sIBM, and there was no staining in
patients with other types of inflammatory myopathies. Anti-
p62 (autophagy) and anti-TDP-43 (degeneration) expressed
predominantly in the vacuoles and were positive in all sIBM
biopsies. As showed by Askanas and Engel [11], immunos-
taining with p62 is linked increasingly to early processes of
sIBM’s pathogenesis, demonstrating the involvement of the
accumulation of p-tau in the early stages of the diseases,
making our finding of the presence of labeling for p62 in all
cases with sIBMa strong indication that this is a goodmarker.
The development of techniques that allow an early and
accurate diagnosis of sIBMwith evaluation of serummarkers
and muscle imaging studies will be important to reduce the
need for more invasive tests, such as muscle biopsy.
For now, the gold standard for diagnosis remains the
muscle biopsy, combined with the typical clinical pattern.
Our study evaluated patients that filled all the clinical criteria
described so far. Future studies with patients in the early
stages of the disease, or nonspecific symptoms, using the
same markers, could demonstrate their sensitivity in early
diagnosis of the disease.
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